-
Sawai Announces Listing of Five Generic Drugs with 10 Strengths
-
Sawai Receives Approvals for Six Generic Drugs with 11 Strengths
-
Sawai Announces Listing of Two Generic Drugs with Three Strengths
-
Sawai Receives Approvals for Three Generic Drugs with Four Strengths
-
Notice of Transfer (Sale of Shares/Equity Interests) of Sawai’s U.S. Subsidiary / Sub-subsidiary (PDF: 390KB)
-
Sawai Announces Listing of a single Generic Drug with Two Strengths
-
Launch of Pitavastatin tablets in the United States – Sawai’s First generic ANDA approval and launch for US market under Paragraph IV–
-
Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP
-
Upsher-Smith Expands Vigadrone® (vigabatrin) Franchise to Include Tablets
-
Upsher-Smith Launches Isotretinoin Capsules, USP
-
Upsher-Smith Completes Sale of Two Migraine Products
-
Upsher-Smith Divests Two Migraine Products
-
Sawai Announces Listing of Two Generic Drugs with Eight Strengths
-
Upsher-Smith Adds Dicyclomine Hydrochloride Capsules, USP to its Product Line
-
Sawai Group Holdings Announces Change of Representative Directors and Corporate Officers (PDF: 151KB)
-
Upsher-Smith Expands Ophthalmic Portfolio with Launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
-
Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
-
Upsher-Smith Launches Dicyclomine Hydrochloride Tablets
-
Sawai Receives Approvals for Three Generic Drugs with 10 Strengths
-
Upsher-Smith Expands Fluoxetine Product Line to Include an Oral Solution
